Atrium Therapeutics prices $50 million private placement at $7.93 per share
On October 7, 2026, Atrium Therapeutics agreed to sell 5,170,384 common shares at $7.93 each, plus pre-funded warrants for up to 1,134,930 shares, to accredited investors, for expected gross proceeds of about $50 million before fees. The company says the proceeds, together with existing cash, will fund operations through 2028, and that shares outstanding will rise to 22,276,027 after the offering, which shareholders should weigh against their stake.
Key points
- 5,170,384 common shares sold at $7.93 per share; pre-funded warrants for up to 1,134,930 shares sold at $7.929 each.
- Expected gross proceeds of about $50 million before placement agent fees and offering expenses; closing expected on or about October 9, 2026.
- Company estimates net proceeds plus existing cash will fund operations through 2028; proceeds are for lead programs, other research, working capital and general corporate purposes.
- Company must file a resale registration statement with the SEC within 50 days of the closing date; 22,276,027 shares will be outstanding after the offering.
The filing
Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.